319 related articles for article (PubMed ID: 30045932)
1. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Margolin K; Morishima C; Velcheti V; Miller JS; Lee SM; Silk AW; Holtan SG; Lacroix AM; Fling SP; Kaiser JC; Egan JO; Jones M; Rhode PR; Rock AD; Cheever MA; Wong HC; Ernstoff MS
Clin Cancer Res; 2018 Nov; 24(22):5552-5561. PubMed ID: 30045932
[No Abstract] [Full Text] [Related]
2. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
3. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Romee R; Cooley S; Berrien-Elliott MM; Westervelt P; Verneris MR; Wagner JE; Weisdorf DJ; Blazar BR; Ustun C; DeFor TE; Vivek S; Peck L; DiPersio JF; Cashen AF; Kyllo R; Musiek A; Schaffer A; Anadkat MJ; Rosman I; Miller D; Egan JO; Jeng EK; Rock A; Wong HC; Fehniger TA; Miller JS
Blood; 2018 Jun; 131(23):2515-2527. PubMed ID: 29463563
[TBL] [Abstract][Full Text] [Related]
4. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
5. A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.
Miller JS; Morishima C; McNeel DG; Patel MR; Kohrt HEK; Thompson JA; Sondel PM; Wakelee HA; Disis ML; Kaiser JC; Cheever MA; Streicher H; Creekmore SP; Waldmann TA; Conlon KC
Clin Cancer Res; 2018 Apr; 24(7):1525-1535. PubMed ID: 29203590
[No Abstract] [Full Text] [Related]
6. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
[TBL] [Abstract][Full Text] [Related]
8. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.
Ng S; Deng J; Chinnadurai R; Yuan S; Pennati A; Galipeau J
Cancer Res; 2016 Oct; 76(19):5683-5695. PubMed ID: 27488533
[TBL] [Abstract][Full Text] [Related]
10. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
Conlon K; Watson DC; Waldmann TA; Valentin A; Bergamaschi C; Felber BK; Peer CJ; Figg WD; Potter EL; Roederer M; McNeel DG; Thompson JA; Gupta S; Leidner R; Wang-Gillam A; Parikh NS; Long D; Kurtulus S; Ho Lee L; Chowdhury NR; Bender F; Pavlakis GN
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799399
[TBL] [Abstract][Full Text] [Related]
12. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.
Doedens AL; Rubinstein MP; Gross ET; Best JA; Craig DH; Baker MK; Cole DJ; Bui JD; Goldrath AW
Cancer Immunol Res; 2016 Sep; 4(9):799-811. PubMed ID: 27485135
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice.
Song Y; Liu Y; Hu R; Su M; Rood D; Lai L
Mol Cancer Ther; 2016 Oct; 15(10):2413-2421. PubMed ID: 27474151
[TBL] [Abstract][Full Text] [Related]
14. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
16. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
17. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses.
Pilones KA; Charpentier M; Garcia-Martinez E; Daviaud C; Kraynak J; Aryankalayil J; Formenti SC; Demaria S
Cancer Immunol Res; 2020 Aug; 8(8):1054-1063. PubMed ID: 32532811
[TBL] [Abstract][Full Text] [Related]
19. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
[TBL] [Abstract][Full Text] [Related]
20. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]